Admin 
Myasthenia Gravis is an autoimmune disease that can occur at any age, but it is more commonly seen in women between the ages of 20 and 40. It is characterized by impaired transmission of nerve impulses from the nerve ending to the muscle fiber and follows a course of remissions and exacerbations. The disease results from an immune-mediated attack against receptors at the neuromuscular junction.
Myasthenia gravis may occur on its own or in association with other autoimmune diseases such as systemic lupus erythematosus and hyperthyroidism. In this condition, antibodies damage acetylcholine receptors at the neuromuscular junction, leading to rapid breakdown and inactivation of acetylcholine and impaired neuromuscular transmission.
The most typical finding in myasthenia gravis is severe muscle fatigue. Patients often report feeling better in the morning, with fatigue increasing rapidly as the day progresses. In addition to marked muscle fatigability, muscle weakness or paralysis may also be present. Weakness of the eye muscles may cause double vision or misalignment of the eyes.
Involvement of the ocular muscles is often the initial manifestation. Weakness may also affect the muscles of the face, lips, tongue, throat, and neck. Ptosis, as well as difficulty with chewing, swallowing, and speaking, are other important symptoms.
A definitive diagnosis of the disease is made using electromyography (EMG).
The treatment of myasthenia gravis has three main objectives:
- To reduce antibody production
- To eliminate circulating antibodies
- To increase the effectiveness of acetylcholine at the neuromuscular junction
Comprehensive evaluation and follow-up of patients with a holistic treatment approach significantly improve quality of life.
Restless Legs Syndrome (RLS)?
Prev post
